Aclaris Therapeutics, Inc. (NASDAQ:ACRS)
| Market Cap | $545.63M+25.1% |
| Revenue (ttm) | $6.40M-59.3% |
| Net Income | -$79.63M+43.8% |
| EPS | -$0.58+58.0% |
| Shares Out | 158.61M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,186,269 |
| Open | $3.44 |
| Previous Close | $3.50 |
| Day's Range | $3.41 - $3.54 |
| 52-Week Range | $2.46 - $6.60 |
| Beta | 0.80 |
| Analysts | Buy |
| Price Target | $7.33(+113.08%) |
| Earnings Date | Feb 25, 2027 |
About ACRS
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating ACRS in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 25, 2027Earnings report
$ACRS stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in ACRS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ACRS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ACRS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ACRS Revenue by Segment
| Personnel | $3.55M | 39.46% |
| Other income | $2.83M | 31.50% |
| Segment Information | $1.48M | 16.46% |
| Licensing | $1.13M | 12.58% |
As of: Q3 2026 (Sep 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New ACRS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ACRS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ACRS
| VTIVanguard Morningstar Total Stock Market ETF | $13.28M |
| IWMiShares Russell 2000 ETF | $10.85M |
| VXFVanguard Extended Market ETF | $5.99M |
| XPHState Street SPDR S&P Pharmaceuticals ETF | $4.15M |
| FESMFidelity Enhanced Small Cap ETF | $3.45M |
| IWOiShares Russell 2000 Growth ETF | $3.41M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from ACRS’s recent data — informational, not investment advice
What’s Behind the Score
News check: Major Phase 2 trial failure in atopic dermatitis, analyst downgrade with 62.5% price target cut, partially offset by new Phase 2b trial initiation.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| XPH | State Street SPDR S&P Pharmaceuticals ETF | 0.88% |
| DWAS | Invesco Dorsey Wright SmallCap Momentum ETF | 0.58% |
| QQQS | Invesco NASDAQ Future Gen 200 ETF | 0.41% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.39% |
| BUSM | EA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | 0.16% |
| PILL | Direxion Daily Pharmaceutical & Medical Bull 3X ETF | 0.14% |
| FSEG | Fidelity Enhanced Small Cap Growth ETF | 0.13% |
| IWC | iShares Micro-Cap ETF | 0.13% |
| VMO.TO | Vanguard Global Momentum Factor ETF | 0.11% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.09% |
| FSEV | Fidelity Enhanced Small Cap Value ETF | 0.06% |
| FESM | Fidelity Enhanced Small Cap ETF | 0.05% |
Weight is the stock’s share of each fund’s holdings.
